Management of coronary artery disease in patients with type 2 diabetes mellitus

被引：14

作者：

Srikanth S. ^{[1
]}

Deedwania P. ^{[1
]}

机构：

[1] Veterans Affairs Central California Health Care System, University of California-San Francisco Program at Fresno, Fresno, CA 93703

来源：

Current Cardiology Reports | 2007年 / 9卷 / 4期

关键词：

Percutaneous Coronary Intervention; Coronary Artery Bypass Graft; Atorvastatin; Fenofibrate; Abciximab;

D O I：

10.1007/BF02938374

中图分类号：

学科分类号：

摘要：

Diabetes mellitus is as much a vascular disease as it is a metabolic disorder. The metabolic abnormalities associated with diabetes include hyperglycemia, and abnormal carbohydrate, fat, and protein handling. These abnormalities increase oxidative stress and activate the renin angiotensin system, which subsequently causes endothelial dysfunction and predisposes to atherosclerosis. Type 2 diabetes has reached epidemic proportions and because of its strong association with coronary artery disease (CAD), it is responsible for increasing cardiovascular morbidity and mortality in the United States. In this article we review some of the evidence and the rationale for comprehensive risk reduction to prevent and treat CAD in individuals with diabetes mellitus. The comprehensive risk reduction strategy includes lifestyle changes, glycemic control, and control of dyslipidemia and hypertension. Advances in revascularization techniques, and superior outcomes of coronary artery bypass grafting as an interventional modality over percutaneous coronary intervention, are discussed. We also identify controversies and issues that currently remain unresolved. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：264 / 271

页数：7

共 39 条

[21]

Collaboration meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients, BMJ, 324, pp. 71-86, (2002)

[22]

Lindstrom J., Eriksson J.G., Valle T.T., Et al., Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial, J Am Soc Nephrol, 14, 7 SUPPL. 2, (2003)

[23]

Grundy S.M., Cleeman J.I., Daniels S.R., Et al., Diagnosis and management of the metabolic syndrome scientific statement: An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement, Circulation, 112, pp. 2735-2752, (2005)

[24]

Franz M.J., Bantle J.P., Beebe C.A., Et al., American Diabetes Association. Nutrition principles and recommendation in diabetes, Diabetes Care, 27, SUPPL. 1, (2004)

[25]

Ryan D.H., Espeland M.A., Foster G.D., Et al., Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): Design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes, Control Clin Trials, 24, pp. 610-628, (2003)

[26]

Turnbull F., Neal B., Algert C., Et al., Blood Pressure Lowering Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials, Arch Intern Med, 165, pp. 1410-1419, (2005)

[27]

Varughese G.I., Lip G.Y., Antihypertensive therapy in diabetes mellitus: Insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists' collaboration meta-analysis, J Hum Hypertens, 19, pp. 851-853, (2005)

[28]

Smith Jr S.C., Allen J., Blair S.N., Et al., AHA/ACC guidelines for secondary prevention for patient with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute, Circulation, 113, pp. 2363-2372, (2006)

[29]

Antman E.M., Anbe D.T., Armstrong P.W., Et al., ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patient with acute myocardial infarction), J Am Coll Cardiol, 44, (2004)

[30]

The final 10-year follow-up results from the BARI randomized trial, J Am Coll Cardiol, 49, pp. 1600-1606, (2007)

← 1 2 3 4 →